Clinical trials: Paclitaxel, completed
Ureteral Cancer, Urothelial Cancer
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.
- Conditions
- Ureteral Cancer, Urothelial Cancer, Bladder Cancer
- Trial name
- NCT03474107
- Testing
- Enfortumab Vedotin, Docetaxel, Vinflunine
- Where
- 158 sites in United States, Argentina and 17 more
- Volunteers
- 608 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non-small Cell Lung Cancer (NSCLC)
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC
The purpose of this study is to evaluate the real-world effectiveness and safety of neoadjuvant nivolumab combined with chemotherapy in Argentinian patients with resectable non-small cell lung cancer (NSCLC)
- Trial name
- NCT07141563
- Testing
- Nivolumab + platinum-based chemotherapy
- Where
- Argentina
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Non Small Cell Lung Cancer
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating…
- Trial name
- CheckMate 816 (NCT02998528)
- Testing
- Nivolumab, Cisplatin, Vinorelbine
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb
Cervical Cancer
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
RATIONALE: Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00980954
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 125 sites in United States, Canada and 2 more
- Volunteers
- 236 people
- Sponsor
- Radiation Therapy Oncology Group
Triple-Negative Breast Cancer
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Study MO39874 is an open-label, Phase IIIb, single arm, global study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received…
- Trial name
- EL1SSAR (NCT04148911)
- Testing
- Atezolizumab, Nab-Paclitaxel
- Where
- 67 sites in Argentina, Chile and 11 more
- Volunteers
- 184 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer
The current standard of first-line chemotherapy in advanced ovarian cancer is the combination of carboplatin AUC 5mg/mL/min and paclitaxel 175 mg.m-².
- Trial name
- EWOC-1 (NCT02001272)
- Testing
- Paclitaxel + Carboplatin every 3 weeks, Carboplatin monotherapy every 3 weeks, Weekly Paclitaxel and Carboplatin
- Where
- 63 sites in Canada, Denmark and 4 more
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Non-Small Cell Lung Cancer
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
- Trial name
- CheckMate 9LA (NCT03215706)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 116 sites in United States, Argentina and 17 more
- Volunteers
- 719 people
- Sponsor
- Bristol-Myers Squibb
High Grade Serous Ovarian, Fallopian Tube
A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer
The purpose of this study is to find out what effects, good or bad, the addition of nivolumab or the combination of nivolumab plus ipilimumab to typical chemotherapy has on the treatment of advanced high-grade serous cancers of…
- Conditions
- High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer
- Trial name
- NCT03245892
- Testing
- Carboplatin and Paclitaxel, Nivolumab, Cytoreductive surgery
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chinese Patients Treated With Agent DCB
An "All-Comers" Study of the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter Used in Real-World Clinical Practice in Chinese Patients
To compile the real-world clinical outcome data for the AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter (Agent DCB) used in percutaneous coronary intervention (PCI) in Chinese patients.
- Trial name
- NCT04085445
- Testing
- AgentTM MONORAILTM Paclitaxel-Coated PTCA Balloon Catheter
- Where
- 9 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with…
- Trial name
- NCT05342636
- Testing
- Pembrolizumab, Coformulation favezelimab/pembrolizumab, MK-4830
- Where
- 46 sites in Brazil, Chile and 11 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung…
- Conditions
- Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02621398
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rutgers, The State University of New Jersey
Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body.
- Conditions
- Locally Advanced Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
- Trial name
- NCT03910387
- Testing
- Gemcitabine, Nab-paclitaxel, Telotristat Ethyl
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Emory University
Breast Cancer Metastatic
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
This is a multicenter, randomized, 2 arm, open label, phase II study. It is designed to compare the efficacy and safety of abemaciclib combined with ET (letrozole or fulvestrant) versus a short course with induction chemotherapy…
- Trial name
- ABIGAIL (NCT04603183)
- Testing
- Abemaciclib, Paclitaxel, Letrozole
- Where
- 31 sites in Italy, Portugal and 1 more
- Volunteers
- 162 people
- Sponsor
- MedSIR
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is commonly observed in southern China, particularly in the Pearl River delta area and the Xijiang River basin in the Guangdong and Guangxi provinces, with an incidence rate as high as 25-50 per…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Cancer
- Trial name
- NCT04004871
- Testing
- Nab-paclitaxel, Cisplatin and Fluorouracil, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Advanced Solid Tumors
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
An open-label, dose-escalation (Part 1), dose-expansion (Part 2) study to assess the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-155 alone and in combination with paclitaxel or docetaxel.
- Trial name
- NCT03595059
- Testing
- ABBV-155, Paclitaxel, Docetaxel
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 168 people
- Sponsor
- AbbVie
Lung Cancer, Non Small Cell Lung Cancer
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and non-small cell lung cancer (NSCLC).
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Lung Cancer
- Trial name
- NCT03177291
- Testing
- Pirfenidone, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Squamous Cell Carcinoma of Head and Neck
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)
Researchers are looking for new ways to treat people with head and neck cancer whose cancer has come back after treatment (recurrent) or whose cancer has spread to other parts of the body (metastatic).
- Trial name
- NCT04428151
- Testing
- Lenvatinib, Pembrolizumab, Docetaxel
- Where
- 120 sites in United States, Australia and 13 more
- Volunteers
- 408 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Neoplasms
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma.
- Trial name
- LEAP-001 (NCT04865289)
- Testing
- Lenvatinib, Pembrolizumab, Paclitaxel
- Where
- 22 sites in China
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Lung Cancer
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
This is an open-label phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of JS004 injection combined with toripalimab and with or without standard chemotherapy in patients with…
- Trial name
- NCT05664971
- Testing
- Recombinant humanized anti-BTLA monoclonal antibody (JS004) injection, Toripalimab, Docetaxel
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Gastric Cancer
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
Fruquintinib once daily in 4 weeks treatment cycle (three weeks on and one week off) in combination with Paclitaxel 80mg/㎡（day1, 8, 15 of 4 weeks cycle) was well tolerated and demonstrated encouraging preliminary clinical…
- Trial name
- FRUTIGA (NCT03223376)
- Testing
- fruquintinib +paclitaxel
- Where
- 7 sites in China
- Volunteers
- 703 people
- Sponsor
- Hutchison Medipharma Limited